PTC Therapeutics PTCT
United StatesHealthcare · BiotechnologyUSD
101.79 USD (+61.0%)
14 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
PTC Therapeutics is a biopharmaceutical company that develops and commercializes therapies for rare and genetic diseases, with a business model focused on innovation and the commercialization of medicines for unmet medical needs.
Key points
from its scores- ✓Strong growth10.0
- ✓Favourable backdrop7.9
- ✕Little or no dividend1.5
- ✕Demanding valuation1.9
- ✕Poor share-price trend2.6
AI analysis
bottom line, main risk, context and newsStrong growth and operating margin are attractive, but high debt and demanding valuation limit near-term upside potential.
PTC Therapeutics shows exceptional revenue growth (101.5%) and a solid operating margin (41.3%), but its high leverage (net debt/EBITDA of 4.61) and demanding valuation (EV/EBITDA of 35.66) create financial and valuation risks in a rising rate environment.
The main risk is the high financial leverage (net debt/EBITDA of 4.61), which in a rising interest rate environment could pressure cash flow and limit the ability to invest in its drug pipeline.
Context and risks
PTC Therapeutics operates in the U.S. biotechnology sector, where regulatory risk is inherent: FDA drug approvals and drug pricing pressure can materially affect revenues. The company has net debt of 4.61 times its EBITDA, amplifying its vulnerability to a rising interest rate environment, although its liquidity position (3.39 ratio) provides some cushion.
Is PTC Therapeutics stock cheap or expensive?
at the analysis dateOn EV / EBITDA, it trades 146% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| EV / EBITDA | 35.7 | 14.5 | +146% |
| Price / sales | 5.2 | 3.4 | +53% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 1.9 out of 10 (median for Healthcare: 4.7).
Average analyst target: 101.79 USD, +61.0% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 4.2 (sector 5.5), Growth 10.0 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 23.6
- EV / EBITDA
- 35.7
- Price / book
- −31.9
- Price / sales
- 5.2
- Market cap
- 5.3B USD
- Enterprise value
- 6.1B USD
Profitability
- ROA
- 2.5%
- Gross margin
- 50.0%
- Operating margin
- 41.3%
- Net margin
- −3.8%
- Free cash flow
- −286.8M USD
- FCF yield
- −5.4%
- Cash conversion
- −168%
Solvency
- Total debt
- 3.0B USD
- Net debt
- 788.8M USD
- Cash
- 2.2B USD
- EBITDA
- 171.2M USD
- Net debt / EBITDA
- 4.61
- Current ratio
- 3.39
- Quick ratio
- 3.20
Growth
- Revenue growth
- +101.5%
- EPS (TTM)
- −0.65 USD
- EPS (forward)
- 2.68 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.49
- Analyst consensus
- Buy (14)
- Target price
- 101.79 USD
- 52-week range
- 61.23 – 90.87
Recent news
All PTCT news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about PTC Therapeutics
Is PTC Therapeutics stock cheap or expensive?
On EV / EBITDA, it trades 146% above the Healthcare median. Valuation score: 1.9 out of 10 (median for Healthcare: 4.7). Average analyst target: 101.79 USD, +61.0% versus the price. This is not investment advice.
What score does PTC Therapeutics get on MeridIAn Screener?
It scores 4.9 out of 10, rank 1,760 of 2,130 (better than 17% of the companies analysed). Its strongest category is Growth (10.0) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
How much is PTC Therapeutics worth on the stock market?
Its market capitalisation is 5.3B USD and its enterprise value, debt included, is 6.1B USD.
How much debt does PTC Therapeutics have?
Its net debt (debt minus cash) is 788.8M USD. That is 4.61 times its EBITDA; the Healthcare median is 1.53.
Does PTC Therapeutics pay a dividend?
It pays no dividend, or almost none.
How has PTC Therapeutics stock performed over the last year?
It has fallen 4.5% over the last year, excluding dividends. Over the last 52 weeks it has traded between 61.23 and 90.87 USD. Past performance does not guarantee future results.
What do analysts think of PTC Therapeutics?
14 analysts cover it; their average recommendation is “Buy” and their average target is 101.79 USD (+61.0% versus the price). It is an estimate, not market data.